Novavax (NVAX) Reports Q2, Issues Operational Update

Go back to Novavax (NVAX) Reports Q2, Issues Operational Update

Novavax (NVAX) shares tumble as Q2 results miss estimates, guidance cut

August 8, 2024 8:57 AM UTC

Novavax (NASDAQ: NVAX) shares plunged 13.8% premarket Thursday after the vaccine maker reported second-quarter results that missed analyst expectations and lowered its full-year revenue guidance.

The company posted adjusted earnings per share of $0.99, falling short of the $1.67 consensus estimate. Revenue came in at $415 million, below the $464.83 million analysts were expecting and down slightly from... More